Targets › PD-1
5 programs from 5 companies in 29 trials: 23 Phase 2, 6 Phase 1; Oncology; next expected readout Sep 2027.
Open in Phaseline: the race on PD-1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Yongxu Jia | Iparomlimab and Tuvonralimab Injection (QL1706) CTLA-4 and PD-1 dual checkpoint inhibitor | CTLA4, PD-1 | Phase 2 | Gastroesophageal Junction Adenocarcinoma | Sep 2027 |
| Qilu Hospital of Shandong University | Iparomlimab and Tuvonralimab (QL1706) Dual CTLA-4 and PD-1 inhibitor | CTLA4, PD-1 | Phase 2 | HER2 Negative | Oct 2027 |
| Tianjin Medical University Cancer Institute and Hospital | Iparomlimab/Tuvonralimab CTLA-4 and PD-1 inhibitor combination | CTLA4, PD-1 | Phase 2 | HCC - Hepatocellular Carcinoma | Aug 2028 |
| West China Hospital | Ivonescimab PD-1 and CTLA-4 dual inhibitor | PD-1, CTLA4 | Phase 2 | Head and Neck Squamous Cell Carcinoma | Dec 2028 |
| Revolution Medicines | Ivonescimab PD-1 and CTLA-4 dual antagonist | PD-1, CTLA4 | Phase 1 | Advanced Solid Tumors; Stomach Cancer Stage IV; Small Cell Lung Cancer; Recurrent or Metastatic Nasopharyngeal Carcinoma … | May 2029 |
Non-Small Cell Lung Cancer (4) Advanced Solid Tumors (1) Stomach Cancer Stage IV (1) Small Cell Lung Cancer (1) Recurrent or Metastatic Nasopharyngeal Carcinoma (1) Rectal Cancer (1) Endometrial Cancer (1) Cutaneous Angiosarcoma (1) Pancreatic Cancer (1) Biliary Tract Cancer (1) Metastatic Endocrine Refractory (1) TNBC (1)
mixed (3), antibody (2)
Revolution Medicines (1) Yongxu Jia (1) Qilu Hospital of Shandong University (1) West China Hospital (1) Tianjin Medical University Cancer Institute and Hospital (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.